A novel method to detect hPG<sub>80</sub> (human circulating progastrin) in the blood

Cappellini, Monica; Flacelière, Maud; Saywell, Véronique; Soulé, Julien; Blanc, Emilie; Belouin, Fanny; Ortiz, Erika; Canterel-Thouennon, Lucile; Poupeau, Sophie; Tigrett, Sylvia; Vire, Bérengère; Liaud, Pierre; Blairvacq, Mélina; Joubert, Dominique; Prieur, Alexandre

doi:10.1039/d1ay00986a

Cited by 6 publications

(9 citation statements)

References 29 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ELISA DxPG 80 .lab kit (ECS-Progastrin, Lausanne, Switzerland) was used to measure hPG 80 levels in all plasma EDTA samples according to the manufacturer’s instruction. The analytical performances of the kit are described in Cappellini et al [ 21 ]. Briefly, the limit of detection (LoD) is at a hPG 80 concentration of 1 pM and the limit of quantitation (LoQ) is at a hPG 80 concentration of 3.3 pM.…”

Section: Methodsmentioning

confidence: 99%

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

Dupuy

Iltache

Rivière

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Alpha-fetoprotein (AFP) is the most widely used biomarker for hepatocellular carcinoma (HCC) prognosis. However, AFP is not useful in establishing a prognosis for patients with a tumor in the early stages. hPG80 (circulating progastrin) is a tumor promoting peptide present in the blood of patients with various cancers, including HCC. In this study, we evaluated the prognostic value of plasma hPG80 in patients with HCC, alone or in combination with AFP. A total of 168 HCC patients were tested prospectively for hPG80 and analyzed retrospectively. The prognostic impact of hPG80 and AFP levels on patient survival was assessed using Kaplan-Meier curves and log-rank tests. hPG80 was detected in 84% of HCC patients. There was no correlation between hPG80 and AFP levels in the training and validation cohorts. Both cohorts showed higher sensitivity of hPG80 compared to AFP, especially at early stages. Patients with high hPG80 (hPG80+) levels (optimal cutoff value 4.5 pM) had significantly lower median overall survival (OS) compared to patients with low hPG80 (hPG80−) levels (12.4 months versus not reached respectively, p < 0.0001). Further stratification by combining hPG80 and AFP levels (cutoff 100 ng/mL) improved prognosis in particular for those patients with low AFP level (hPG80−/AFP+ and hPG80−/AFP−, 13.4 months versus not reached respectively, p < 0.0001 and hPG80+/AFP+ and hPG80+/AFP−, 5.7 versus 26 months respectively, p < 0.0001). This was corroborated when analyses were performed using the BCLC staging especially at early stages. Our findings show that hPG80 could serve as a new prognostic biomarker in HCC. Used in combination with AFP, it improves the stratification of the patients in good and poor prognosis, especially for those patients with negative AFP and early-stage HCC.

show abstract

Section: Methodsmentioning

confidence: 99%

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

Dupuy

Iltache

Rivière

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…hPG 80 (human circulating progastrin) is a pan tumor biomarker that has been found to be over-expressed in multiple malignancies. hPG 80 synthesis is product of overexpression of GAST gene in cancer cells and human circulating progastrin can now be measured accurately with help of DxPG 80 Enzyme-Linked Immunosorbent Assay (ELISA) based test [ 8 , 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…We acknowledge that PPI usage could induce gastrin hyper secretion (hypergastrinemia); however, to our knowledge, there is no publication showing an increase in hPG 80 during PPI usage. Furthermore, as described in Cappellini [ 16 ], we would like to mention that the kit (DxPG 80 ) that was used to measure hPG 80 (human circulating progastrin) does not recognize any other forms of gastrin peptides, avoiding any risk of false positivity due to PPI usage and hypergastrinemia. Nonetheless, we are currently setting up a clinical study to answer this very question.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors

Chauhan

Prieur²,

Kolesar

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Current blood-based biomarkers for neuroendocrine neoplasms (NENs) lack both sensitivity and specificity. Human circulating progastrin (hPG80) is a novel biomarker that can be easily measured in plasma by ELISA. This study is the first to examine hPG80 in NENs. Plasma hPG80 was quantified from 95 stage IV NEN patients, using DxPG80 technology (ECS Progastrin, Switzerland) and compared with hPG80 concentrations in two cohorts of healthy donor controls aged 50–80 (n = 252) and 18–25 (n = 137). Median hPG80 in NENs patients was 5.54 pM compared to 1.5 pM for the 50–80 controls and 0.29 pM the 18–25 cohort (p < 0.0001). Subgroup analysis revealed median hPG80 levels significantly higher than for either control cohort in neuroendocrine carcinoma (NEC; n = 25) and neuroendocrine tumors (NET; n = 70) including the small-cell lung cancer (SCLC) sub-cohort (n = 13). Diagnostic accuracy, estimated by AUCs, was high for NENs, as well as both sub-groups (NEC/NET) when compared to the younger and older control groups. Plasma hPG80 in NENs may be a diagnostic blood biomarker for both low- and high-grade NENs; further study is warranted. A prospective multi-center trial is ongoing in NET to evaluate hPG80 as a means of monitoring disease (NCT04750954).

show abstract

“…A prospective study, which was analyzed retrospectively, was performed on a total of 1,546 patients and 557 healthy blood donors, enabling the determination of hPG 80 , with the DxPG80 IVD ELISA kit developed by BIODENA CARE ( 15 ). In this study, the levels of hPG 80 (circulating progastrin) were determined in 11 different epithelial and non-epithelial cancers (colorectal, breast, uterus, ovary, prostate, kidney, pancreas, esophagus/stomach, liver, melanoma and lung).…”

Section: Introductionmentioning

confidence: 99%

hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study

Casile

Passildas

Vire³

et al. 2023

Front. Neurol.

Self Cite

View full text Add to dashboard Cite

BackgroundCurrently, the long-term prognosis and survival rate of patients with high-grade glial tumors remains poor and there are no biomarkers. hPG80 (circulating progastrin) secreted into the blood by tumor cells has been widely studied in colorectal cancer. Its involvement in tumorigenesis has been demonstrated in the literature. Moreover, according to a recent study, hPG80 is expressed in the blood of cancer patients at a significantly higher concentration than in the control group composed of healthy blood donors.MethodsThe PROGLIO study is a pilot, single-center, longitudinal study that primarily seeks to evaluate circulating plasma hPG80 concentrations over time in patients with high-grade glial tumors. A fasting blood sample will be taken on the start and end day of radiotherapy and during the adjuvant chemotherapy (every 3 cycles). Follow-up monitoring will be performed for 9 months, with a blood sample taken every 3 months on the day of the follow-up MRI. The study plans to recruit 30 patients and recruitment started in February 2022.Trial registrationClinicalTrials.gov, ID NCT05157594; registered on October 27, 2021.

show abstract

A novel method to detect hPG₈₀ (human circulating progastrin) in the blood

Abstract: hPG80 (human circulating progastrin) is produced and released by cancer cells. We recently reported that hPG80 is detected in the blood of patients with cancers from different origins, suggesting its...

Cited by 6 publications

References 29 publications

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors

hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study

Contact Info

Product

Resources

About

A novel method to detect hPG80 (human circulating progastrin) in the blood

Abstract: hPG80 (human circulating progastrin) is produced and released by cancer cells. We recently reported that hPG80 is detected in the blood of patients with cancers from different origins, suggesting its...

Cited by 6 publications

References 29 publications

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors

hPG80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study

Contact Info

Product

Resources

About

A novel method to detect hPG₈₀ (human circulating progastrin) in the blood